Neopharmed Gentili Deal History & Licensing Activity
Neopharmed Gentili is a life sciences. Over the past three years, Neopharmed Gentili has been involved in 1 licensing and acquisition transaction, with a primary focus on Small Molecules (2 deals). The company currently has 1 active clinical trial, primarily in Rare Disease.
Deals (12mo)
1
Active Trials
1
Top Modality
Small Molecules
Focus Area
Rare Disease
Neopharmed Gentili Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Neopharmed Gentili in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| navenibart | BioCryst Pharmaceuticals, Inc. | Small Molecules | Phase 3 | license | May 2026 |
Neopharmed Gentili Pipeline Focus
Therapeutic areas and modalities where Neopharmed Gentili is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Neopharmed Gentili Clinical Pipeline
Neopharmed Gentili has 1 active clinical trial across 1 development phase.
1
Unknown
See How Your Asset Matches Neopharmed Gentili's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Neopharmed Gentili Licensing & Deal Activity
Neopharmed Gentili is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Neopharmed Gentili ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Neopharmed Gentili include Rare Disease (2 deals and trials). In terms of modality, Neopharmed Gentili has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Neopharmed Gentili and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Neopharmed Gentili's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.